LINK-A lncRNA activates HIF1α signaling and inhibits podocyte cell apoptosis in diabetic nephropathy. 2019

Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China.

Previous studies have revealed that long intergenic non-coding RNA for kinase activation (LINK-A), a long non-coding RNA (lncRNA) promotes disease progression in triple-negative breast cancer by activating hypoxia-inducible factor 1α (HIF1α). However, the activation of HIF1α has also been demonstrated to improve diabetic nephropathy. It is therefore reasonable to expect that LINK-A may also participate in diabetic nephropathy. In the current study, the expression of LINK-A lncRNA and HIF1α was determined in renal biopsies of patients with diabetic nephropathy. LINK-A lncRNA and HIF1α expression levels were detected by reverse transcription quantitative (RT-q) PCR and ELISA in diabetic patients without complications and used as controls. Correlations between LINK-A lncRNA and HIF1α expression were analyzed using Pearson's correlation coefficient. Effects of lncRNA and HIF1α overexpression on LINK-A lncRNA expression, HIF1α expression and cell apoptosis were assessed using RT-qPCR, western blotting and a cell apoptosis assay. The results revealed that LINK-A lncRNA and HIF1α were downregulated in patients with diabetic nephropathy, as well as in diabetic patients without complications. The lowest expression of LINK-A lncRNA and HIF1α were observed in healthy controls. A positive correlation was identified between LINK-A lncRNA and HIF1α in both patients groups, but not in the control group. LINK-A lncRNA and HIF1α overexpression inhibited the apoptosis of mouse podocyte cells under a high glucose treatment. LINK-A lncRNA overexpression also promoted HIF1α expression in mouse podocyte cells, while HIF1α overexpression did not significantly affect LINK-A lncRNA expression. In conclusion, LINK-A lncRNA may activate HIF1α signaling resulting in the improvement of diabetic nephropathy treatment.

UI MeSH Term Description Entries

Related Publications

Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
January 2018, Drug design, development and therapy,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
October 2020, Molecular and cellular probes,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
November 2016, Cell death & disease,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
December 2017, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
January 2023, Open medicine (Warsaw, Poland),
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
January 2019, International journal of clinical and experimental pathology,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
November 2018, Biochemical and biophysical research communications,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
August 2017, International journal of molecular sciences,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
January 2019, Diabetes, metabolic syndrome and obesity : targets and therapy,
Jing Yang, and Lihua Li, and Shijun Hong, and Zhu Zhou, and Wenxing Fan
August 2019, Experimental & molecular medicine,
Copied contents to your clipboard!